药物联合序贯治疗绝经后骨质疏松症的研究进展

李 海芳, 张 鑫帅
河北北方学院 河北省张家口市 075000

参考

[1]Brown JP. Long-Term Treatment of Postmenopausal Osteoporosis.Endocrinol Metab(Seoul).2021 Jun;36(3):544-552.[2]Xu X, Zhang P,Li X,Liang Y,et al.MicroRNA expression profiling in an ovariectomized rat model of postmenopausal osteoporosis before and after estrogen treatment.Am J Transl Res.2020 Aug 15;12(8):4251-4263.[3]Black DM,Rosen CJ.Clinical Practice.Postmenopausal Osteoporosis.N Engl J Med.2016 Jan 21;374(3):254-62.[4]Leder BZ,Tsai JN,Uihlein AV,et al.Denosumab and teriparatide transitions in postmenopausal osteoporosis(the DATA-Switch study):extension of a randomised controlled trial.Lancet.2015 Sep 19;386(9999):1147-55.[5]Sun Y,Li Y,Li J,et al.Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis:A Meta-Analysis.Front Pharmacol.2022 May 24;13:888208.[6]Yuan F,Peng W,Yang C,et al.Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis:A meta-analysis.Int J Surg.2019 Jun;66:1-11.[7]Yang D,Tan J,Long Y,et al.Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis:a prospective study.Aging Clin Exp Res.2023 Mar;35(3):531-539.[8]Deal C,Omizo M,Schwartz EN,et al.Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis:results from a 6-month double-blind placebo-controlled trial.J Bone Miner Res.2005 Nov;20(11):1905-11.[9]Adami S,San Martin J,Muñoz-Torres M,et al.Effect of raloxifene after recombinant teriparatide[hPTH(1-34)]treatment in postmenopausal women with osteoporosis.Osteoporos Int.2008 Jan;19(1):87-94.[10]Miller SA,St Onge EL,Whalen KL.Romosozumab:A Novel Agent in the Treatment for Postmenopausal Osteoporosis.J Pharm Technol.2021 Feb;37(1):45-52.[11]McClung MR,Bolognese MA,Brown JP,Reginster JY,Langdahl BL, Shi Y,Timoshanko J,Libanati C,Chines A,Oates MK.Skeletal responses to romosozumab after 12months of denosumab.JBMR Plus.2021 Jun 3;5(7):e10512.